Editas Medicine (EDIT) Income towards Parent Company (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Income towards Parent Company of -$25.1 million for Q3 2025, up 59.58% year-over-year from -$15.7 million in Q3 2024, and up 51.66% quarter-over-quarter from -$52.0 million in Q2 2025.
Editas Medicine (EDIT) Income towards Parent Company (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Income towards Parent Company for 11 consecutive years, with -$25.1 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Income towards Parent Company rose 59.58% year-over-year to -$25.1 million; the TTM figure through Dec 2025 stood at -$155.9 million (up 35.34% YoY), while the FY2024 annual figure was -$626.1 million, down 30.37% from the prior year.
- Income towards Parent Company rose to -$25.1 million in Q3 2025 per EDIT's latest filing, from -$52.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$22.2 million in Q4 2023 and bottomed at -$4.0 billion in Q1 2022.
- Historically, Income towards Parent Company has averaged -$444.1 million across 5 years, with a median of -$67.6 million in 2024.
- Annual changes were most pronounced in 2022 — Income towards Parent Company sank 3901.13% — and 2023, when it soared 92.91%.
- Editas Medicine's Income towards Parent Company stood at -$33.7 million in 2021, then sank by 71.62% to -$57.9 million in 2022, then soared by 61.66% to -$22.2 million in 2023, then sank by 105.52% to -$45.6 million in 2024, then surged by 44.92% to -$25.1 million in 2025.
- Business Quant data shows EDIT's Income towards Parent Company at -$25.1 million in Q3 2025, -$52.0 million in Q2 2025, and -$78.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -25.12 Mn |
| Jun 30, 2025 | -51.96 Mn |
| Mar 31, 2025 | -78.85 Mn |
| Dec 31, 2024 | -45.60 Mn |
| Sep 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -67.61 Mn |
| Mar 31, 2024 | -65.80 Mn |
| Dec 31, 2023 | -22.19 Mn |
| Sep 30, 2023 | -132.82 Mn |
| Jun 30, 2023 | -506.50 Mn |
| Mar 31, 2023 | -283.96 Mn |
| Dec 31, 2022 | -57.87 Mn |
| Sep 30, 2022 | -1.59 Bn |
| Jun 30, 2022 | -1.11 Bn |
| Mar 31, 2022 | -4.01 Bn |
| Dec 31, 2021 | -33.72 Mn |
| Sep 30, 2021 | -67.50 Mn |
| Jun 30, 2021 | -130.67 Mn |
| Mar 31, 2021 | -100.10 Mn |
| Dec 31, 2020 | -58.99 Mn |